Gout drug may halt dangerous seizure clusters in epilepsy patients
NCT ID NCT07318870
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether probenecid, a medicine used for gout, can stop cluster seizures in people with focal epilepsy. Participants are patients aged 6 to 50 who are in the hospital for presurgical monitoring and have their usual seizure medications paused to trigger seizures. The goal is to see if a single dose of probenecid prevents further seizures for 12 hours, using video-EEG to track results.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL EPILEPSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a night of soft sounds sharpen the epileptic brain?
- Brain recordings reveal how we keep tabs on others — a window into social navigation
- New brain sensor aims to stop seizures in Drug-Resistant epilepsy
- New pill aims to curb focal seizures in adults
- Virtual tours may help spare memory in epilepsy surgery
- New epilepsy drug RAP-219 enters final testing phase